ARIAD PHARMACEUTICALS INC's ticker is ARIA and the CUSIP is 04033A100. A total of 207 filers reported holding ARIAD PHARMACEUTICALS INC in Q3 2016. The put-call ratio across all filers is 2.19 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $47,000 | -76.5% | 3,460 | -76.3% | 0.00% | – |
| Q3 2016 | $200,000 | +952.6% | 14,592 | +467.3% | 0.00% | – |
| Q2 2016 | $19,000 | -48.6% | 2,572 | -56.4% | 0.00% | – |
| Q1 2016 | $37,000 | -77.7% | 5,901 | -77.7% | 0.00% | – |
| Q4 2015 | $166,000 | +315.0% | 26,469 | +294.6% | 0.00% | – |
| Q3 2015 | $40,000 | -4.8% | 6,708 | +34.2% | 0.00% | – |
| Q2 2015 | $42,000 | 0.0% | 5,000 | 0.0% | 0.00% | – |
| Q1 2015 | $42,000 | -89.9% | 5,000 | -91.7% | 0.00% | – |
| Q4 2014 | $414,000 | +37.5% | 60,300 | +8.2% | 0.00% | – |
| Q3 2014 | $301,000 | -37.7% | 55,750 | -26.4% | 0.00% | – |
| Q2 2014 | $483,000 | -52.3% | 75,750 | -39.8% | 0.00% | -100.0% |
| Q1 2014 | $1,013,000 | +147.7% | 125,750 | +109.8% | 0.00% | – |
| Q4 2013 | $409,000 | -90.2% | 59,950 | -73.6% | 0.00% | -100.0% |
| Q3 2013 | $4,185,000 | +38.6% | 227,412 | +31.7% | 0.01% | +40.0% |
| Q2 2013 | $3,020,000 | – | 172,634 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 12,850,000 | $175,916,000 | 40.51% |
| Consonance Capital Management LP | 8,695,742 | $119,045,000 | 11.46% |
| Tamarack Advisers, LP | 3,700,000 | $49,358,000 | 7.76% |
| Opaleye Management Inc. | 1,045,000 | $14,306,000 | 7.49% |
| Granite Point Capital Management, L.P. | 457,415 | $6,262,000 | 2.44% |
| Redmile Group, LLC | 2,138,471 | $29,276,000 | 2.33% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 206,010 | $2,820,000 | 2.17% |
| Palo Alto Investors LP | 2,587,617 | $35,424,000 | 2.06% |
| PRICE MICHAEL F | 940,000 | $12,869,000 | 1.71% |
| HighVista Strategies LLC | 638,086 | $8,735,000 | 1.62% |